Floatz logo

her2bi-armed activated t cells

Prostate Carcinoma Metastatic in the Bone

Barbara Ann Karmanos Cancer InstituteCell therapyPhase 2Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
31/ 100
Competitive Position
95/ 100

Competitive context

252 Active assets in the Prostate Carcinoma Metastatic in the Bone cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Mayo Clinic
Phase 4BBB
Fluciclovine
VA Greater Los Angeles Healthcare System
Phase 4BBB
LEUPROLIDE
Mayo Clinic
Phase 4BBB
Abiraterone Acetate
Mayo Clinic
Phase 4BB
PREDNISONE TABLETS
Mayo Clinic
Phase 4BB

View all 50 →

Same molecule, other indications

her2bi-armed activated t cells is also rated in:

castration-resistant prostate carcinomaDormant
CC
Indicative ·
46 / 100
View asset →
PSA ProgressionDormant
CC
Indicative ·
46 / 100
View asset →
prostate adenocarcinomaDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →